Home / IL-6 / Recombinant Equine IL-6 Protein

Recombinant Equine IL-6 Protein

Catalog #: 1886-EL
6 Citations Datasheet / COA / SDS

Discontinued Product

1886-EL has been discontinued.
View all IL-6 products.
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (6)
FAQs
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Equine IL-6 Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using T1165.85.2.1 mouse plasmacytoma cells. Nordan, R.P. et al. (1987) J. Immunol. 139:813. The ED50 for this effect is ≤ 2.00 ng/mL.
Source
E. coli-derived equine IL-6 protein
Phe26-Met208, with an N-terminal Met
Accession #
Q95181.2
N-terminal Sequence
Analysis
Met
Predicted Molecular Mass
21 kDa

Product Datasheets

You must select a language.

x

1886-EL (with carrier)

Product Datasheet
COA
SDS

You must select a language.

x

1886-EL/CF (carrier free)

Discontinued Product

1886-EL

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: IL-6

Interleukin-6 (IL-6) is a pleiotropic, alpha -helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression (1-5). Mature equine IL-6 is 181 amino acids (aa) in length and shares 59%, 39%, and 40% aa sequence identity with human, mouse, and rat IL-6, respectively IL-6 (6). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha, triggering IL-6 R alpha association with gp130 and gp130 dimerization (7). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (8). Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage (5). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha (5). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alpha is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes (2, 5). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alpha but not from other cytokines that use gp130 as a co-receptor (5, 9). IL-6, along with TNF-alpha and IL-1, drives the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease (1-5). When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis (1, 2, 5). IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise (2). In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells (1, 10).

References
  1. Mansell, A. and B.J. Jenkins (2013) Cytokine Growth Factor Rev. 24:249.
  2. Schuett, H. et al. (2009) Thromb. Haemost. 102:215.
  3. Erta, M. et al. (2012) Int. J. Biol. Sci. 8:1254.
  4. Garbers, C. et al. (2012) Cytokine Growth Factor Rev. 23:85.
  5. Mihara, M. et al. (2012) Clin. Sci. (Lond.) 122:143.
  6. Swiderski, C.E. et al. (2000) Vet. Immunol. Immunopathol. 77:213.
  7. Murakami, M. et al. (1993) Science 260:1808.
  8. Muller-Newen, G. (2003) Sci. STKE 2003:PE40.
  9. Mitsuyama, K. et al. (2006) Clin. Exp. Immunol. 143:125.
  10. Cerutti, A. et al. (1998) J. Immunol. 160:2145.
Long Name
Interleukin 6
Entrez Gene IDs
3569 (Human); 16193 (Mouse); 24498 (Rat); 399500 (Porcine); 280826 (Bovine); 403985 (Canine); 102138971 (Cynomolgus Monkey); 100034196 (Equine); 493687 (Feline); 463288 (Primate); 100008733 (Rabbit)
Alternate Names
B-cell differentiation factor; B-cell stimulatory factor 2; BSF2; BSF-2; CDF; CTL differentiation factor ; HSF; hybridoma growth factor; IFNB2; IFN-beta-2; IL6; IL-6; Interferon beta-2; interleukin 6 (interferon, beta 2); interleukin BSF-2; interleukin-6; MGI-2A

Citations for Recombinant Equine IL-6 Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

6 Citations: Showing 1 - 6
Filter your results:

Filter by:

  1. Interleukin-6 upregulates extracellular matrix gene expression and transforming growth factor ?1 activity of tendon progenitor cells
    Authors: Altmann, N;Bowlby, C;Coughlin, H;Belacic, Z;Sullivan, S;Durgam, S;
    BMC musculoskeletal disorders
    Species: Equine
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Equine Arteritis Virus in Monocytic Cells Suppresses Differentiation and Function of Dendritic Cells
    Authors: NA Moyo, D Westcott, R Simmonds, F Steinbach
    Viruses, 2023-01-16;15(1):.
    Species: Equine
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Infection of monocytes with European porcine reproductive and respiratory syndrome virus (PRRSV-1) strain Lena is significantly enhanced by dexamethasone and IL-10
    Authors: H Singleton, SP Graham, JP Frossard, KB Bodman-Smi, F Steinbach
    Virology, 2018-03-02;0(0):.
    Species: Porcine
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Effects of priming with cytokines on intracellular survival and replication of Rhodococcus equi in equine macrophages
    Authors: LJ Berghaus, S Giguère, AI Bordin, ND Cohen
    Cytokine, 2017-12-12;102(0):7-11.
    Species: Equine
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Effects of high mobility group box protein-1, interleukin-1beta, and interleukin-6 on cartilage matrix metabolism in three-dimensional equine chondrocyte cultures.
    Authors: Ley C, Svala E, Nilton A, Lindahl A, Eloranta ML, Ekman S, Skioldebrand E
    Connect. Tissue Res., 2010-11-30;52(4):290-300.
    Species: Equine
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Serum interleukin-6 (IL-6) and IL-10 concentrations in normal and septic neonatal foals.
    Authors: Burton AB, Wagner B, Erb HN, Ainsworth DM
    Vet. Immunol. Immunopathol., 2009-05-18;132(2):122-8.
    Species: N/A
    Sample Types: Antibody
    Applications: ELISA Standard

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Equine IL-6 Protein

There are currently no reviews for this product. Be the first to review Recombinant Equine IL-6 Protein and earn rewards!

Have you used Recombinant Equine IL-6 Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review